Joseph H. Schwab

Joseph H. Schwab

Auto-generated profile, based on publicly available information

Joseph H. Schwab

Massachusetts General Hospital

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2016 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
PDF file
NPNuno Rui Paulino Pereira
Nuno Rui Paulino Pereira
SJStein J. Janssen
Stein J. Janssen
EDEva van Dijk
Eva van Dijk
MHMitchel B. Harris
Mitchel B. Harris
FHFrancis J. Hornicek
Francis J. Hornicek
JSJoseph H. Schwab
Joseph H. Schwab
Current prognostication models for survival estimation in patients with metastatic spine disease lack accuracy. Identifying new risk factors could improve existing models. We assessed factors associated with survival in patients surgically treated for spine metastases, created a classic scoring algorithm, nomogram, and boosting algorithm, and tested the predictive accuracy of the three created algorithms at estimating survival. We included 649 patients from two tertiary care referral centers in this retrospective study (2002 to 2014). A multivariate Cox model was used to identify factors independently associated with survival. We created a classic scoring system, a nomogram, and a boosting (i.e., machine learning) algorithm and calculated their accuracy by receiver operating characteristic analysis. Older age (hazard ratio [HR], 1.01; p = 0.009), poor performance status (HR, 1.54; p = 0.001), primary cancer type (HR, 1.68; p < 0.001), >1 spine metastasis (HR, 1.32; p = 0.009), lung and/or liver metastasis (HR, 1.35; p = 0.005), brain metastasis (HR, 1.90; p < 0.001), any systemic therapy for cancer prior to a surgical procedure (e.g., chemotherapy, immunotherapy, hormone therapy) (HR, 1.65; p < 0.001), higher white blood-cell count (HR, 1.03; p = 0.002), and lower hemoglobin levels (HR, 0.92; p = 0.009) were independently associated with decreased survival. The boosting algorithm was best at predicting survival on the training data sets (p < 0.001); the nomogram was more reliable at estimating survival on the test data sets, with an accuracy of 0.75 (30 days), 0.73 (90 days), and 0.75 (365 days). We identified risk factors associated with survival that should be considered in prognostication. Performance of the boosting algorithm and nomogram were comparable on the testing data sets. However, the nomogram is easier to apply and therefore more useful to aid surgical decision-making. Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.

1 January 2012 in Spine
Verified
Journal Article
Closed access
SBStefano Boriani
Stefano Boriani
SBStefano Bandiera
Stefano Bandiera
RCRoberto Casadei
Roberto Casadei
LBLuca Boriani
Luca Boriani
RDRakesh Md Donthineni
Rakesh Md Donthineni
JSJoseph H. Schwab
Joseph H. Schwab
Study Design. This is a retrospective review of 49 cases of giant cell tumor (GCT) of the mobile spine treated surgically. Objective. Our goal was to determine which factors influenced local recurrence. Summary of Background Data. GCT is a benign, locally aggressive tumor that rarely occurs in the spine. The management of local recurrence can be challenging. Methods. We performed a retrospective analysis of GCTs of the mobile spine managed between 1970 and 2005. Median follow-up was 145 months with a minimum of 2 years or until death. We used the Kaplan-Meier method to test whether Enneking stage, surgery type, and surgical margin had statistically significant impact on local recurrence. The log rank test was used for comparison, and a P value of less than 0.05 was deemed significant. Results. Of the 49 patients, 11 (22%) local recurrences occurred. The latest recurrence occurred at 60 months. Age less than 25 years was associated with a worse relapse-free survival (P = 0.03). En bloc resection was associated with better local control with Enneking stage III tumors (P = 0.01); however, intralesional resection provided adequate control of Enneking stage II tumors. There were 6 (12%) cases of metastasis, and 2 patients died from the progression of their disease. One patient died from the complications of the surgery. Conclusion. En bloc resection should be considered for Enneking stage III GCTs of the mobile spine. The choice of en bloc resection must be balanced with the inherent risks of the procedure. Intralesional resection of Enneking stage II tumors provides adequate local control. Patients should be followed for at least 5 years because local relapse can occur late.

1 November 2009 in Spine
Verified
Journal Article
Closed access
JSJoseph H. Schwab
Joseph H. Schwab
JHJohn Healey
John Healey
PRPeter Rose
Peter Rose
JCJorge Casas-Ganem
Jorge Casas-Ganem
PBPatrick J. Boland
Patrick J. Boland
Retrospective case series. The purpose of this study was to evaluate factors that contribute to improved local control and survival. In addition, we sought to define the expected morbidity associated with treatment. Sacral chordomas are rare tumors presumed to arise from notochordal cells. Local recurrence presents a major problem in the management of these tumors and it has been correlated with survival. Resection of sacral tumors is associated with significant morbidity. Forty-two patients underwent resection for sacral chordoma between 1990 and 2005. Twelve patients had their initial surgery elsewhere. There were 12 female and 30 male patients. The proximal extent of the sacrectomy was at least S2 in 32 patients. Median survival was 84 months, and 5-year disease-free (DFS) and disease-specific survival (DSF) were 56% and 77%, respectively. Local recurrence (LR) and metastasis occurred in 17 (40%) and 13 (31%) patients, respectively. Local recurrence (P=0.0001), metastasis (P=0.0001), prior resection (P=0.046), and higher grade (P=0.05) were associated with a worse DSF. Prior resections (P=0.0001) and intralesional resections (P=0.01) were associated with a higher rate of LR. Intralesional resections were associated with a lower DSF (P=0.0001). Wide contaminated margins treated with cryosurgery and/or radiation were not associated with a higher LR rate. Rectus abdominus flaps were associated with decreased wound complications (P=0.01). Thirty-one (74%) patients reported that they self catheterize; and 16 (38%) patients required bowel training, while an additional twelve (29%) patients had a colostomy. Twenty-eight (67%) patients reported sexual dysfunction. Two (5%) patients died due to sepsis. Intralesional resection should be avoided as it is associated with a higher LR rate and worse survival. Rectus abdominus flaps ought to be considered as they lower the wound complication rate. Sacral resection is associated with significant morbidity.

4 August 2022 in JBJS Open Access
Verified
Journal Article
Open access
DBDavid N. Bernstein
David N. Bernstein
AKAditya V. Karhade
Aditya V. Karhade
CBChristopher M. Bono
Christopher M. Bono
JSJoseph H. Schwab
Joseph H. Schwab
MHMitchel B. Harris
Mitchel B. Harris
DTDaniel G. Tobert
Daniel G. Tobert
Update: This article was updated on November 10, 2023, because of a previous error. The authors of this study uncovered a documentation error in the data used for the analysis when conducting future research. While the statistical analyses are accurate, all included patients were –in fact –not just from “new patient encounters” but also from “follow-up visits.” In light of this finding, the title now reads “Sociodemographic Factors Are Associated with Patient-Reported Outcome Measure Completion in Orthopaedic Surgery: An Analysis of Completion Rates and Determinants”, and all references to “new patients” or “new patient encounters” have been removed from the text (including in the limitations paragraph). An erratum has been published: JBJS Open Access. 2022;7(3):e22.00026ER. Background: Patient-reported outcome measures (PROMs) and, specifically, the Patient-Reported Outcomes Measurement Information System (PROMIS), are increasingly utilized for clinical research, clinical care, and health-care policy. However, completion of these outcome measures can be inconsistent and challenging. We hypothesized that sociodemographic variables are associated with the completion of PROM questionnaires. The purposes of the present study were to calculate the completion rate of assigned PROM forms and to identify sociodemographic and other variables associated with completion to help guide improved collection efforts. Methods: All orthopaedic patients at a single academic medical center were identified from 2016 to 2020. On the basis of subspecialty and presenting condition, patients were assigned certain PROMIS forms and legacy PROMs. Demographic and clinical information was abstracted from the electronic medical record. Bivariate analyses were performed to compare characteristics among those who completed assigned PROMs and those who did not. A multivariable logistic regression model was created to determine which variables were associated with successful completion of assigned PROMs. Results: Of the 219,891 patients, 88,052 (40%) completed all assigned PROMs. Patients who did not activate their internet-based patient portal had a 62% increased likelihood of not completing assigned PROMs (odds ratio [OR], 1.62; 95% confidence interval [CI], 1.58 to 1.66; p < 0.001). Non-English-speaking patients had a 90% (OR, 1.90; 95% CI, 1.82 to 2.00; p < 0.001) increased likelihood of not completing assigned PROMs at presentation. Older patients (≥65 years of age) and patients of Black race had a 23% (OR, 1.23; 95% CI, 1.19 to 1.27; p < 0.001) and 24% (OR, 1.24; 95% CI, 1.19 to 1.30; p < 0.001) increased likelihood of not completing assigned PROMs, respectively. Conclusions: The rate of completion of PROMs varies according to sociodemographic variables. This variability could bias clinical outcomes research in orthopaedic surgery. The present study highlights the need to uniformly increase completion rates so that outcomes research incorporates truly representative cohorts of patients treated. Furthermore, the use of these PROMs to guide health-care policy decisions necessitates a representative patient distribution to avoid bias in the health-care system. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

1 October 2012 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
PDF file
JSJoseph H. Schwab
Joseph H. Schwab
DSDempsey S. Springfield
Dempsey S. Springfield
KRKevin A. Raskin
Kevin A. Raskin
HMHenry J. Mankin
Henry J. Mankin
FHFrancis J. Hornicek
Francis J. Hornicek
We reviewed the literature to determine the important advances related to primary bone tumors during the past few years. In the present update, we will discuss malignant tumors (including Ewing sarcoma, osteosarcoma, chondrosarcoma, and chordoma) and benign tumors (including benign cartilaginous tumors, giant cell tumor of bone, and aneurysmal bone cysts). With regard to malignant tumors, much effort has been focused on finding new potential targets for systemic therapy. Additional efforts have been made in an attempt to identify disease markers that will correlate with outcome. For benign tumors, the focus has been on less aggressive treatment over time. For example, twenty-five years ago, giant cell tumor of bone was often treated with en bloc excision, whereas now, local curettage with or without an adjuvant is more routine. Presently, drugs that act on osteoclasts, such as denosumab (an antibody to RANK ligand), may result in management of giant cell tumors without surgery particularly with very large or recurrent tumors. We will review some of the newer aspects of detection and treatment of some of the more common primary malignant and benign bone tumors. ### Ewing Sarcoma Ewing sarcoma is a member of the Ewing family of tumors (EFT) and, unlike most other primary tumors of bone, has a characteristic translocation most commonly involving the eleventh and twenty-second chromosomes. The protein product of that translocation is EWS-FLI1 and has been postulated to act as an aberrant transcription factor driving the pathogenesis of Ewing sarcoma1. EWS-FLI1 forms a transcriptional complex with RNA helicase A (RHA), and this complex has been implicated in the pathogenesis of Ewing sarcoma. A recent study in Nature Medicine blocked the binding of EWS-FLI1 to RHA and subsequently induced apoptosis and inhibited growth in a xenograft model, providing proof of the concept that this interaction may be important in …

1 June 2009
Verified
Journal Article
Closed access
JSJoseph Schwab
Joseph Schwab
CACristina Antonescu
Cristina Antonescu
PBPatrick Boland
Patrick Boland
JHJohn Healey
John Healey
ARAndrew Rosenberg
Andrew Rosenberg
ZDZhenfeng Duan
Zhenfeng Duan